AI Healthcare Statistics 2026
By Axis Intelligence Research
Co-authors: Jennifer Miller & Sarah Mitchell | Last updated: July 10, 2026 | License: CC BY 4.0
The global AI in healthcare market spans $37–$54 billion in 2026, depending on whether analysts count only clinical AI software or sweep in pharmaceutical R&D platforms and AI-embedded hardware. The FDA has authorized 1,451 AI-enabled medical devices through December 2025 — 295 cleared in 2025 alone, a single-year record. U.S. physician AI adoption reached 63% by January 2026, up 16 percentage points in nine months. And the world’s first end-to-end AI-discovered drug published peer-reviewed Phase IIa data in Nature Medicine in June 2025, then entered Phase III trials in July 2026.
Quick Answer
AI in healthcare is no longer an experimental category. The MarketsandMarkets June 2026 report values the market at $36.67 billion in 2026 and projects $194.79 billion by 2031 at a 39.7% CAGR. Among U.S. physicians, Doximity’s 2026 State of AI in Medicine Report found 63% actively using AI by January 2026 — but only 8% working in institutions with a well-defined AI policy. U.S. digital health startups raised $14.2 billion in 2025, with AI companies capturing 54% of all funding. And Insilico Medicine’s rentosertib became the first AI-designed drug to publish positive randomized Phase IIa data in Nature Medicine, progressing to Phase III in July 2026.
Key Findings
- The AI in healthcare market spans $36.67–$53.61 billion in 2026 across major research firms, depending on scope. MarketsandMarkets’ clinical-only definition puts it at $36.67 billion; Grand View Research’s broader definition including pharma AI arrives at $50.7 billion; Mordor Intelligence estimates $53.61 billion. All three project the market clearing $100 billion before 2031.
- The FDA has authorized 1,451 cumulative AI-enabled medical devices through December 2025, with 295 authorized in 2025 alone — a single-year record. Of the cumulative total, 1,104 (76%) are radiology devices, and the first foundation-model-powered clinical AI (Aidoc’s CARE1™) received clearance in February 2025.
- U.S. physician AI adoption rose from 47% in March–April 2025 to 63% by November 2025–January 2026, a 16-point gain in nine months (Doximity, n=3,151). Only 8% of those physicians work in institutions with a well-defined AI governance policy — the gap Axis Intelligence Research quantifies as HADI™ 582.8.
- The PRAIM trial — published in Nature Medicine in January 2025 across 463,094 women at 12 German sites — found AI-supported mammography screening detected breast cancer at a rate 17.6% higher than standard double reading, while projecting a 56.7% reduction in radiologist workload. It remains the strongest piece of clinical evidence in healthcare AI.
- Insilico Medicine’s rentosertib, the first drug where both the therapeutic target and the molecule were AI-discovered, showed a mean +98.4 mL improvement in lung function (FVC) versus −20.3 mL in the placebo group in its Phase IIa trial, published in Nature Medicine June 3, 2025. Phase III began July 2026.
Two Proprietary Axis Intelligence Research Metrics
AHCAI™ v1.1 — AI Healthcare Clinical Adoption Index
Axis Intelligence Research’s AHCAI™ scores six healthcare AI domains across three dimensions simultaneously: how widely deployed they are, how strong the clinical evidence is, and whether measurable outcomes have been independently validated. The index answers a question no single market size figure can: where does clinical AI actually work at scale, and where is deployment running ahead of evidence?
Formula (v1.1):
AHCAI™ = (Deployment % × 0.35) + (Evidence Score normalized × 0.40) + (Outcome Score normalized × 0.25)
All three components are normalized to 0–100 before weighting, so the maximum possible score is 100. Evidence scoring: RCT or prospective multicenter trial = 100, peer-reviewed retrospective or survey with disclosed methodology = 60, industry survey only = 20. Outcome scoring: independently validated = 100, partially validated = 75, mixed evidence = 50, not validated = 0.
v1.1 update note: The normalization method has been corrected from v1.0 to apply consistent 0–100 scaling across all three components. Two inputs changed: Clinical Documentation deployment updated to 55% (Doximity 2026 scribe data), and Drug Discovery outcome score upgraded to 100 following the Nature Medicine Phase IIa publication of rentosertib (June 2025).
| Rank | Healthcare Domain | Deployment % | Evidence | Outcome | AHCAI™ v1.1 |
|---|---|---|---|---|---|
| 1 | Medical Imaging / Radiology | 76% | RCT (100) | Validated (100) | 91.6 |
| 2 | Drug Discovery / R&D | 30% | RCT (100) | Validated (100) | 75.5 |
| 3 | Administrative Automation | 75% | Peer-reviewed (60) | Partial (75) | 69.0 |
| 4 | Clinical Documentation (AI Scribes) | 55% | Peer-reviewed (60) | Validated (100) | 68.2 |
| 5 | Predictive Analytics (sepsis/readmission) | 48% | Peer-reviewed (60) | Mixed (50) | 53.3 |
| 6 | Patient-Facing AI / Chatbots | 71% | Survey only (20) | Not validated (0) | 32.8 |
Source: Axis Intelligence Research AHCAI™ v1.1, July 2026. Primary inputs: FDA AI/ML device database; McKinsey Q4 2025 GenAI Healthcare Survey; PRAIM Nature Medicine 2025; CAQH 2025 Index; Nature Medicine rentosertib trial June 2025; ECRI 2026; Doximity 2026. CC BY 4.0.
The most counterintuitive finding: Drug Discovery (AHCAI 75.5) now ranks second despite only 30% deployment breadth — because the Phase IIa clinical evidence is genuinely strong. Patient-facing chatbots score last (32.8) despite being the second-most-deployed category, because ECRI named chatbot misuse the single greatest health technology hazard of 2026, and no prospective clinical trial has validated their patient outcomes at scale.
Jennifer Miller: The jump in Drug Discovery’s rank between v1.0 and v1.1 isn’t a formula change — it’s the rentosertib data. A published, randomized, placebo-controlled Phase IIa trial in a disease with no current reversive therapies is not a pilot. It’s the first real evidence that end-to-end AI drug discovery produces clinically meaningful results in humans. The AHCAI is designed to reward exactly that kind of evidence.
HADI™ v1.0 — Healthcare AI Deployment Gap Index
Axis Intelligence Research’s HADI™ measures how far ahead clinical AI deployment has outpaced institutional governance readiness. It is the metric that no market size report publishes, because it’s not a growth story — it’s an accountability prompt.
Formula:
HADI™ = (Physician AI Adoption Rate × Daily-Use Rate Among Adopters) ÷ Institutional Policy Clarity Rate × 100
Inputs, all from Doximity’s 2026 State of AI in Medicine Report (n = 3,151 U.S. physicians, 15 specialties, November 2025–January 2026):
| Input | Value |
|---|---|
| Physician AI Adoption Rate | 63% |
| Daily-Use Rate among AI-adopting physicians | 74% |
| Physicians in institutions with well-defined AI policy | 8% |
HADI™ = (0.63 × 0.74) ÷ 0.08 × 100 = 582.8
According to Axis Intelligence Research’s HADI™ v1.0, the clinical AI governance gap stands at 582.8 as of Q1 2026. Roughly six physicians are using AI daily in institutions without a defined governance policy for every one operating inside a policy-defined environment. A score of 100 would indicate deployment and governance in rough parity.
HADI™ is released CC BY 4.0. Cite as: Axis Intelligence Research. “Healthcare AI Deployment Gap Index v1.0.” axis-intelligence.com/ai-healthcare-statistics/. July 2026.
Jennifer Miller: The HADI™ number is the kind of metric that makes compliance officers uncomfortable in the right way. It isn’t measuring something theoretical. The Doximity data shows physicians using AI daily — for literature retrieval, ambient scribing, prior authorization correspondence — in institutions where the legal, ethical, and clinical governance frameworks are, by the physicians’ own account, either nonexistent or confusing. That is not a product gap. It is a liability waiting to be triggered.
How Big Is the AI in Healthcare Market?
Market size estimates for AI in healthcare span a factor of three across major research firms — not because their methods are wrong, but because they define the category differently. This article maps the divergence rather than picking one figure and presenting it as fact.
The 2026 Market Range
| Source | 2025 Estimate | 2026 Estimate | Long-term Projection | CAGR |
|---|---|---|---|---|
| MarketsandMarkets (clinical-narrow) | $25.88B | $36.67B | $194.79B by 2031 | 39.7% |
| Grand View Research (broad) | $36.7B | $50.7B | $505.6B by 2033 | 38.9% |
| Mordor Intelligence (broad) | $40.14B | $53.61B | $251.36B by 2031 | 36.21% |
| McKinsey (annual U.S. savings potential) | N/A | N/A | $200–$360B/year | N/A |
Source: MarketsandMarkets (June 2026); Grand View Research (2026); Mordor Intelligence (2026); McKinsey Global Institute generative AI in pharma report (January 2024). All figures retrieved July 2026.
The McKinsey savings figure ($200–$360 billion in annual U.S. healthcare savings) is more actionable than any TAM projection because it is grounded in documented waste — $265.6 billion in administrative costs (JAMA), clinical inefficiency, and diagnostic error — rather than extrapolated growth rates. It represents the ceiling on what AI could recover, not a market revenue forecast.
What Drives the Analyst Range?
Narrow definitions count only purpose-built clinical AI software deployed at the point of care. Broad definitions add AI in pharmaceutical R&D platforms (drug target identification, molecular design), AI embedded in imaging hardware (a CT scanner with built-in pathology triage is one product at MarketsandMarkets, split across segments at Grand View), and AI tools in health insurance and claims processing. Adding pharma AI alone shifts the 2025 baseline by roughly $10–$15 billion. Neither scope is wrong; both need to be stated.
Axis Intelligence Research uses MarketsandMarkets as the conservative clinical floor and Mordor/Grand View as the broad ceiling. The consensus midpoint for 2026 sits near $45 billion.
Regional Breakdown
North America holds the largest regional share — 42.4% per MarketsandMarkets (2025), 54% per Grand View Research using its broader scope. The U.S. market alone was valued at $8.65 billion in 2025 (MarketsandMarkets U.S. report) and is projected at $43.30 billion by 2030 at a 38.0% CAGR.
Asia Pacific is the fastest-growing region by every firm’s projection, with CAGRs of 39–42% through 2031, driven by aging populations in Japan and South Korea, China’s government-backed healthcare AI expansion, and India’s pharmaceutical industry. Fortune Business Insights put Asia Pacific at 21% of global revenue in 2025 ($8.28 billion), growing to $12 billion in 2026.
Cloud-based deployment held 63.2% of market share in 2025 (MarketsandMarkets), the largest deployment model, driven by scalability and processing demands of large imaging AI models.
Jennifer Miller: The three-firm spread in market size isn’t noise — it’s signal. When MarketsandMarkets says $36.67 billion and Grand View says $50.7 billion for the same year, the $14 billion gap is almost entirely the pharma AI segment. That matters because pharma AI (drug discovery, molecular design, clinical trial optimization) is where the most reproducible clinical evidence is now emerging, and where the investment is most concentrated. A market map that excludes it understates where the real action is.
How Many AI-Enabled Medical Devices Has the FDA Cleared?
The FDA maintains a public registry of AI/ML-enabled medical devices it has authorized — the most objective primary indicator of how many AI tools have met the regulatory standard for clinical use in the United States.
As of the December 2025 registry update, cited by The Imaging Wire (March 12, 2026):
- 1,451 cumulative AI-enabled medical devices authorized since tracking began in 1995
- 295 devices authorized in 2025 alone — the highest single-year total on record
- 1,104 devices (76%) are radiology devices
- Q4 2025 alone: 72 devices cleared, of which 55 (76%) were radiology
A peer-reviewed analysis published in PMC (Keller et al., 2025) analyzed all 168 ML-enabled Class II devices authorized in 2024: 94.6% cleared via the 510(k) pathway; median review time was 162 days for 510(k), 372 days for De Novo; only 29.2% of devices reported both sensitivity and specificity data; just 15.5% provided demographic data on validation cohorts. That last figure — a demographic transparency rate of 15.5% — is the accountability gap the MDPI cross-sectional analysis (3.6% race/ethnicity disclosure across 692 devices through 2023) confirmed at scale.
FDA AI Authorizations by Company — Radiology (Cumulative through December 2025)
| Rank | Company | Radiology AI Authorizations |
|---|---|---|
| 1 | GE HealthCare (incl. Bay Labs, Caption Health, MIM Software) | 120 |
| 2 | Siemens Healthineers (incl. Varian) | 89 |
| 3 | Philips (incl. DiA Analysis, TomTec) | 50 |
| 4 | Canon (incl. Vital Images, Olea) | 45 |
| 5 | United Imaging | 38 |
| 6 | Aidoc | 31 |
| 7 | DeepHealth (incl. Quantib, iCAD) | 28 |
Source: The Imaging Wire, citing FDA AI-enabled device list updated through December 2025. Retrieved July 2026.
Two Regulatory Firsts in 2025
In February 2025, Aidoc’s CARE1™ foundation model became the first foundation-model-powered clinical AI to receive FDA clearance — a meaningful shift from narrow single-task models toward context-aware reasoning tools. In December 2025, the FDA qualified its first AI-based tool for use inside drug development clinical trials: a cloud platform for liver biopsy scoring in NASH/MASH trials, establishing the formal precedent for AI within drug development submissions themselves.
Jennifer Miller: The radiology concentration — 76% of all FDA-cleared AI devices — is what happens when you have 25 years of regulatory experience in one specialty and 5 years in most others. The clearance queue is a lagging indicator. The more important signal in the 2025 data is the foundation model clearance and the first drug-development AI qualification. Those two expand the regulatory surface area in ways that will make the 2027 and 2028 device lists look very different from today’s.
What Do Physicians Think About AI in 2026?
Doximity’s 2026 State of AI in Medicine Report is the most rigorous measurement of U.S. physician AI attitudes at scale: 3,151 physicians across 15 specialties, surveyed twice — March–April 2025 and November 2025–January 2026 — to track the trajectory over nine months.
Adoption Is Accelerating Faster Than Policy
- 63% of physicians surveyed in November 2025–January 2026 reported currently using AI in practice, up from 47% in March–April 2025 — a 16-point gain in nine months
- 94% are using AI or interested in doing so; only 5% express no interest
- 37% of all surveyed physicians use AI at least daily; among adopters, 74% use it daily, and 36% use it multiple times per day
- 71% cite accuracy and reliability as their top concern about AI outputs
- 47% report their institution’s AI policies are confusing or “still evolving”
- Only 8% work in institutions with a well-defined AI governance policy — the HADI™ denominator
What Physicians Are Actually Using AI For
The most important pattern: physicians are deploying AI for administrative relief first, complex diagnostics a distant second.
| Use case | January 2026 cohort | April 2025 cohort | Change |
|---|---|---|---|
| Literature search | 35% | 22% | +13 pp |
| Voice-based documentation / AI scribes | 29% | 20% | +9 pp |
| Insurance correspondence / prior authorizations | Growing | Baseline | Increasing |
| Patient record summarization | Growing | Baseline | Increasing |
Source: Doximity 2026 State of AI in Medicine Report, Business Wire (March 17, 2026). Retrieved July 2026.
90% of all surveyed physicians believe AI can reduce after-hours “pajama time” — the EHR charting that bleeds into physicians’ personal evenings. 23% say it already has. Among physicians who have adopted AI, 75% report reduced administrative workload and improved job satisfaction, and 69% say it has contributed to improved patient care and outcomes.
Specialty Adoption Rates
Among the 15 specialties studied, neurologists lead at 64%, followed by gastroenterologists at 61% and internal medicine at 60%. Family medicine physicians are the highest-frequency adopters: 88% of family medicine AI users use it daily, with half using it multiple times per day.
This distribution matters. The specialties with the highest AI adoption are not the ones with the most FDA-cleared diagnostic AI devices. Neurologists use AI primarily for literature search and documentation, not neural imaging interpretation. The clinical frontier and the administrative adoption wave are running on separate tracks.
Healthcare AI Investment: Where the Money Went
2025 U.S. Digital Health Venture Capital
Rock Health’s year-end 2025 report found U.S. digital health startups raised $14.2 billion in 2025, a 35% increase over $10.5 billion in 2024 and the highest annual total since 2022. The AI concentration inside that number is the more important figure:
- AI-focused digital health companies captured 54% of total 2025 funding, up from 37% in 2024
- Non-AI digital health companies raised $6.53 billion — marginally below the $6.62 billion they raised in 2024 (−1.3%)
- The entire net increase in digital health venture capital accrued to AI
- 2025 saw 26 megadeals (rounds over $100 million) and 15 newly minted unicorns, up from 6 the prior year
- Average Series C deal size for AI startups: $83.7 million, versus $52.1 million for non-AI peers — a 61% premium
Source: Rock Health 2025 Year-End Digital Health Funding Report, via Healthcare Dive (January 13, 2026) and Fierce Healthcare (January 12, 2026). Retrieved July 2026.
Q1 2026 Momentum
Digital health startups raised $4 billion across 110 deals in Q1 2026 — the strongest first quarter since the pandemic peak (Rock Health Q1 2026 recap, via Fierce Healthcare, April 8, 2026). Average deal size reached $36.7 million, the highest quarterly average Rock Health has tracked since Q4 2021. Twelve companies captured 59% of total quarterly funding via megadeals. The top three funded value propositions in 2025 — non-clinical workflow, clinical workflow, and data infrastructure — collectively drew over 55% of all funding, all three driven by AI enablement.
Government Investment and Policy
Federal activity is reinforcing private capital on two fronts:
In February 2026, the U.S. Department of Health and Human Services announced that nearly 500 million health records had been exchanged through the TEFCA national interoperability network — up from roughly 10 million in January 2025. HHS explicitly framed this data liquidity as a prerequisite for AI deployment at scale.
In April 2026, the CDC published its FY 2026–2030 AI Strategy, outlining four pillars: accelerating AI adoption for disease surveillance and outbreak detection, strengthening AI governance and public trust, advancing enterprise data platforms, and building an AI-ready public health workforce.
The CPT 2026 code set includes 288 new codes covering digital health and AI services, and CMS has expanded payment policies for AI-enabled devices — the reimbursement infrastructure lagging clinical AI deployment by the widest margin of any structural barrier.
Clinical Evidence: What the Research Actually Shows
Market size and adoption statistics describe the scale of deployment. They say nothing about whether that deployment is working. This section covers only evidence from peer-reviewed studies with disclosed methodology.
Medical Imaging — The Strongest Evidence Base
PRAIM Trial — Nature Medicine, January 2025
The largest real-world AI mammography study ever conducted: 463,094 women, 12 German sites, 119 radiologists, prospective design. Key results:
- AI-supported screening group (260,739 women): cancer detection rate 6.7 per 1,000
- Standard double-reading control (201,079 women): 5.7 per 1,000
- Relative improvement: +17.6% (95% CI: +5.7% to +30.8%) — statistically superior
- AI group recall rate: 37.4 per 1,000 versus 38.3 in control — noninferior
- Simulated AI triage scenario: 56.7% reduction in radiologist workload while maintaining detection rates
This is not a promising pilot. It is prospective, multicenter, peer-reviewed evidence at scale. It is the benchmark every other healthcare AI application is measured against.
The AI-STREAM trial (Nature Communications, March 2025) confirmed in a Korean multicenter prospective study that AI assistance in single-reading mammography improved radiologist sensitivity while maintaining specificity — addressing the historical trade-off between sensitivity and recall rate. A standalone AI reader study from Seoul National University Hospital (4,184 examinations) showed AI achieving a cancer detection rate of 17.4 per 1,000 versus 14.6 per 1,000 for radiologists alone in post-mastectomy surveillance, the first large-scale evidence of AI outperforming radiologists as a standalone reader in a specific clinical context.
Clinical Documentation — Consistent Administrative Signal
AI ambient scribes address the most documented problem in U.S. medicine: the 2–1 ratio of EHR time to patient time (for every hour of patient care, physicians average two hours of EHR desk work). Key data points:
- AI scribes reduced in-visit documentation time by approximately 20% and after-hours charting by 30% (Pearl Health analysis, 2025 deployment data)
- Among behavioral health clinicians using AI tools: 82% feel less administratively burdened, 76% report better care delivery, 71% see more patients (Freed 2025 Clinician Survey, n=500+)
- 42% of U.S. physicians reported burnout symptoms in the AMA’s most recent survey, down from the 62.8% pandemic peak but still elevated
- The CAQH 2025 Index — covering 600+ provider organizations representing 63% of insured lives — found healthcare administrative automation avoided $258 billion in administrative costs in 2024, with a remaining $21 billion savings opportunity through full automation of currently manual transactions
Source: CAQH 2025 Index. JAMA analysis estimated $265.6 billion in total U.S. annual administrative waste — the single largest waste category in U.S. healthcare.
Sepsis Prediction — Promising but Context-Dependent
The COMPOSER model (UC San Diego Health), evaluated in a prospective before-and-after study in npj Digital Medicine (March 2024), reported a 17% relative reduction in in-hospital sepsis mortality and a 10% increase in bundle compliance over five months. A 2025 PMC systematic review of 28 sepsis AI studies found mixed outcomes: models achieve 70–85% accuracy under favorable conditions, but performance in community hospitals frequently falls below the threshold at which false-positive burden undermines clinical utility. The honest summary: AI sepsis prediction works in academic medical centers with high-quality EHR data. Generalizability to community hospitals remains unvalidated.
The Bot Wars Problem — Administrative AI’s Documented Downside
The Peterson Health Technology Institute’s April 2026 report documented what it termed “bot wars” in administrative AI:
- AI-assisted coding tools increase billing intensity by enabling higher-complexity documentation — inflating provider revenues while triggering payer countermeasures
- Payers are responding with across-the-board downcoding and blanket reimbursement reductions
- Prior authorization AI has not reduced system-level costs — it has shifted them. Each submission cycle still costs providers $20–$30 and health plans $40–$50 per cycle
- Participants described automated exchanges that multiply communications volume without resolving the underlying questions
The ECRI 2026 Top 10 Health Technology Hazards Report ranked AI chatbot misuse as the single greatest health technology hazard of 2026, with over 40 million daily AI health queries occurring outside any clinical oversight. Patient-facing AI is the most deployed category outside radiology and the least clinically validated — exactly the combination that earns a AHCAI™ score of 32.8.
Jennifer Miller: The bot wars finding from PHTI is among the most important in the 2026 data. It punctures the assumption that deploying AI in a broken administrative process will reduce total system costs. It can produce a faster, more expensive broken process. The efficiency case for administrative AI is real — CAQH’s $258 billion in avoided costs is not a projection, it is a calculation from 600 real organizations. But the distribution of that efficiency depends heavily on how the tools are implemented and who captures the savings.
AI Drug Discovery: The First Peer-Reviewed Clinical Proof
As of early 2026, more than 173 AI-originated drug programs are in clinical development — up from approximately 24 in late 2023. The shift from preclinical to clinical pipeline happened faster than most analysts projected three years ago.
The Rentosertib Milestone
On June 3, 2025, Nature Medicine published Phase IIa results for rentosertib — a TNIK inhibitor for idiopathic pulmonary fibrosis developed by Insilico Medicine’s generative AI platform, Pharma.AI. Both the target (TNIK, a novel kinase not previously known to be relevant in IPF) and the molecule were identified and designed by AI. The trial was multicenter, double-blind, randomized, and placebo-controlled.
Key outcomes from the 71-patient trial:
- Patients receiving 60 mg QD rentosertib: mean FVC improvement of +98.4 mL at 12 weeks
- Placebo group: mean FVC decline of −20.3 mL
- Insilico progressed from project initiation to preclinical candidate in 12–18 months across 22 programs from 2021 to 2024, versus the traditional 2.5–4 years, testing only 60–200 molecules per program
In July 2026, Insilico initiated Phase III trials for rentosertib — the first end-to-end AI drug discovery program to advance into late-stage development.
The broader pipeline: AI-designed molecules are showing 80–90% Phase I success rates compared with 40–65% for traditionally designed compounds (PMC, Clinical and Translational Science, February 2025) — though this is based on 21 completed Phase I trials, a statistically limited dataset. No AI-discovered drug has yet received full FDA approval.
The McKinsey Global Institute has estimated that generative AI could generate $60 billion to $110 billion per year in economic value for the pharmaceutical and medical-product industries, largely through accelerated early discovery and faster regulatory submission processes.
Jennifer Miller: The rentosertib result is not a pilot study or an industry press release — it is a peer-reviewed, randomized, placebo-controlled trial in a disease with no current therapies that reverse disease progression. The +98.4 mL FVC improvement versus −20.3 mL in placebo is a real clinical signal. The question for the next 24 months is whether Phase III replicates it. If it does, it changes the baseline assumption for every pharma R&D budget conversation. That is why Drug Discovery now ranks second on the AHCAI™, behind only radiology.
The Healthcare Workforce Crisis: Why AI Is Structural, Not Optional
The case for AI in healthcare is not primarily a technology argument. It is a workforce arithmetic argument.
Structural shortage (primary sources):
- WHO projects a global shortfall of 10 million health workers by 2030
- HRSA’s December 2025 workforce projections forecast shortages across behavioral health, nursing, and allied health through 2038
- U.S.-specific 2025 projections: 84,930 physician shortage, 250,710 RN shortage, 81,330 LPN shortage, 14,600 mental health counselor shortage
- 65%+ of U.S. hospitals report running below full capacity due to staffing shortages
- 2 in 5 healthcare workers say their jobs feel unsustainable (Indeed Pulse of Healthcare, December 2025)
What AI can realistically address: AI scribes recover 40–60% of documentation time per clinician. Diagnostic AI reduces per-study radiologist workload by up to 56.7% in optimized deployments (PRAIM). Predictive analytics reduces unnecessary hospitalizations. None of these replace clinicians — they change the math on how many patients a clinician can safely serve.
What AI cannot address: The physical shortage of trained professionals, geographic maldistribution of care, pipeline constraints in medical and nursing education, and the systemic factors — reimbursement gaps, scope-of-practice laws, student debt loads — that drive early career departure.
Equity, Bias, and the Validation Gap
The most important underreported story in AI healthcare is not market size. It is demographic representation in validation data.
A 2025 MDPI cross-sectional analysis of 692 FDA-authorized AI/ML devices found:
- Only 3.6% reported race or ethnicity of validation cohorts
- Fewer than 1% provided socioeconomic information about validation populations
- Fewer than 2% linked to peer-reviewed performance publications
The Keller et al. (2025) peer-reviewed analysis of 168 devices authorized in 2024 found only 15.5% provided demographic data. AI tools authorized for clinical use have been validated primarily on populations that do not represent the full breadth of patients they will serve.
The access dimension compounds the representation problem: over 75 million Americans lack access to primary care; 122 million live in mental health provider shortage areas; globally, 73% of patients have experienced care delays, waiting an average of 70 days for an appointment. The AI tools with the strongest clinical evidence — radiology AI — are concentrated in well-resourced academic medical centers, not in the underserved communities where the access gap is largest.
Methodology
All statistics in this article were sourced from documents fetched and read during a production session on July 10, 2026. No figure was drawn from model memory.
Primary sources used:
- MarketsandMarkets AI in Healthcare Market report (June 2026), via PR Newswire
- Grand View Research AI in Healthcare Market report (2026)
- Mordor Intelligence AI in Healthcare Market (2026)
- Rock Health 2025 Year-End Digital Health Funding Report (via Healthcare Dive, January 13, 2026)
- Rock Health Q1 2026 Digital Health Funding Recap (via Fierce Healthcare, April 8, 2026)
- Doximity 2026 State of AI in Medicine Report (Business Wire, March 17, 2026)
- The Imaging Wire, citing FDA AI-enabled device list through December 2025 (March 12, 2026)
- Keller et al. (2025), “Machine Learning-Enabled Medical Devices Authorized by the US FDA in 2024,” PMC12730494
- PRAIM trial, Nature Medicine (January 2025), PMC11922743
- Insilico Medicine rentosertib Phase IIa, Nature Medicine (June 3, 2025), DOI 10.1038/s41591-025-03743-2
- Insilico Medicine Phase III announcement (PR Newswire, July 2026)
- HHS TEFCA press release (hhs.gov, February 2026)
- CDC FY 2026–2030 AI Strategy (cdc.gov, April 2026)
- CAQH 2025 Index (caqh.org)
- ECRI 2026 Top 10 Health Technology Hazards Report
- Peterson Health Technology Institute April 2026 administrative AI report
- McKinsey Global Institute generative AI in pharma (January 2024); McKinsey agentic AI biopharma (December 2025)
- JAMA administrative waste analysis (jamanetwork.com/journals/jama/fullarticle/2752664)
- WHO global health workforce data (who.int)
- HRSA December 2025 workforce projections (bhw.hrsa.gov)
- MDPI cross-sectional analysis, 692 FDA AI devices demographic disclosure (2025)
AHCAI™ methodology: Three-component composite using normalized 0–100 scales. Deployment % from cross-survey synthesis (FDA database, McKinsey Q4 2025, Doximity 2026). Evidence scores: RCT/prospective multicenter=100, peer-reviewed retrospective=60, industry survey only=20. Outcome validation: independently validated=100, partial=75, mixed=50, not validated=0. Weights: 35/40/25.
HADI™ methodology: Cross-source ratio using three Doximity 2026 survey inputs. U.S.-specific; does not represent global physician governance readiness.
Limitations: Market size projections vary by factor of 1.5× across firms due to scope differences — cited ranges, not single point estimates. Clinical AI performance in academic medical centers does not generalize to community hospitals without independent validation. Survey-based adoption figures may overstate depth of integration. Drug discovery Phase I success rate data is based on 21 completed trials (statistically limited).
About This Dataset
The accompanying CSV (ai-healthcare-statistics-2026.csv) contains every quantitative claim in this article as a tidy, machine-readable row, with source organization, source document, URL, retrieval date, as-of date, is_primary, axis_calculated, and method_note columns. The AHCAI™ and HADI™ computed rows carry full formula disclosure in method_note.
License: CC BY 4.0 — free to use, share, and adapt with attribution. Citation format: Axis Intelligence Research (2026). AI Healthcare Statistics 2026. axis-intelligence.com/ai-healthcare-statistics/. CC BY 4.0. Temporal coverage: 2024–2026 empirical data; forecasts to 2033–2034.
Cite This Page
APA: Axis Intelligence Research, & Miller, J. (2026). AI healthcare statistics 2026: Market size, clinical evidence, physician adoption & investment data. Axis Intelligence Research. https://axis-intelligence.com/ai-healthcare-statistics/
MLA: Axis Intelligence Research and Jennifer Miller. “AI Healthcare Statistics 2026: Market Size, Clinical Evidence, Physician Adoption & Investment Data.” Axis Intelligence Research, 2026, axis-intelligence.com/ai-healthcare-statistics/.
Chicago: Axis Intelligence Research and Jennifer Miller. “AI Healthcare Statistics 2026: Market Size, Clinical Evidence, Physician Adoption & Investment Data.” Axis Intelligence Research. Last modified July 10, 2026. https://axis-intelligence.com/ai-healthcare-statistics/.
Embeddable blockquote:
“According to Axis Intelligence Research, the global AI in healthcare market spans $37–$54 billion in 2026. The FDA has authorized 1,451 AI-enabled medical devices through December 2025, 76% in radiology. U.S. physician AI adoption reached 63% by January 2026 — but Axis Intelligence Research’s HADI™ index of 582.8 shows roughly six physicians are using AI daily in institutions without a governance policy for every one in a policy-defined environment.” — Axis Intelligence Research, July 2026. [axis-intelligence.com/ai-healthcare-statistics/]
Frequently Asked Questions
How big is the AI in healthcare market in 2026?
The global AI in healthcare market spans $36.67 billion to $53.61 billion in 2026, depending on the scope used by each research firm. MarketsandMarkets uses a clinical-only definition and estimates $36.67 billion; Grand View Research and Mordor Intelligence use broader definitions that include pharmaceutical AI and AI-embedded devices, arriving at $50.7 billion and $53.61 billion respectively. All three project the market clearing $100 billion before 2031.
What percentage of physicians use AI in 2026?
According to Doximity’s 2026 State of AI in Medicine Report — which surveyed 3,151 U.S. physicians across 15 specialties from November 2025 to January 2026 — 63% of physicians reported currently using AI in their practice, up from 47% nine months earlier. Among AI adopters, 74% use it daily.
How many FDA-cleared AI medical devices exist?
The FDA has authorized 1,451 cumulative AI-enabled medical devices through December 2025, per its publicly maintained registry cited by The Imaging Wire (March 2026). Of these, 1,104 (76%) are radiology devices. In 2025 alone, 295 devices were authorized — a single-year record.
What is the AHCAI™ index?
The AI Healthcare Clinical Adoption Index (AHCAI™) is an Axis Intelligence Research proprietary composite metric scoring six healthcare AI domains across deployment breadth (35% weight), clinical evidence strength (40%), and outcome validation status (25%). In v1.1, Medical Imaging/Radiology scores highest at 91.6 (strong RCT evidence, validated outcomes), Drug Discovery second at 75.5 (Nature Medicine Phase IIa confirmed), and Patient-Facing Chatbots last at 32.8 (second-most deployed, not clinically validated — and ECRI’s top health technology hazard of 2026).
What is the HADI™ index?
The Healthcare AI Deployment Gap Index (HADI™) is an Axis Intelligence Research proprietary metric computed as (physician AI adoption rate × daily-use rate among adopters) ÷ institutional policy clarity rate × 100. Using Doximity 2026 data, the current score is 582.8 — meaning roughly six physicians use AI daily in institutions without a clear governance policy for every one in a policy-defined institution.
What are the biggest risks in healthcare AI?
The ECRI 2026 report named AI chatbot misuse the single greatest health technology hazard of 2026, with over 40 million daily AI health queries outside clinical oversight. Other documented risks: algorithmic bias in tools validated on non-representative populations (only 3.6% of FDA-authorized devices disclose race/ethnicity of validation cohorts per MDPI 2025); administrative AI triggering billing intensity increases without reducing system costs (PHTI April 2026); and governance gaps quantified by the HADI™ index of 582.8.
Has any AI-designed drug been approved?
No AI-discovered drug has yet received full FDA approval. However, Insilico Medicine’s rentosertib — where both the therapeutic target (TNIK) and the molecule were AI-designed — published positive Phase IIa results in Nature Medicine on June 3, 2025, showing +98.4 mL FVC improvement versus −20.3 mL in the placebo group. Phase III began in July 2026, making it the first AI-discovered drug to enter late-stage development.
How much venture capital went into healthcare AI in 2025?
Rock Health’s 2025 year-end report found U.S. digital health startups raised $14.2 billion in 2025, a 35% increase over 2024. AI-focused companies captured 54% of that total — up from 37% in 2024. The entire net increase in digital health venture capital accrued to AI companies; non-AI digital health VC was essentially flat year-over-year.
What does the PRAIM trial show about AI in radiology?
The PRAIM trial — published in Nature Medicine in January 2025, involving 463,094 women across 12 German sites — found AI-supported mammography screening detected breast cancer at a rate 17.6% higher than standard double reading (6.7 vs. 5.7 per 1,000 women), while a simulated AI triage scenario projected a 56.7% reduction in radiologist workload. It is the largest real-world AI mammography study ever conducted and represents the strongest clinical evidence in healthcare AI.
Why does AI in healthcare have a governance problem?
Only 8% of U.S. physicians surveyed by Doximity in January 2026 work in institutions with a well-defined AI policy, while 63% are actively using AI in practice and 74% of adopters use it daily. This gap — quantified by Axis Intelligence Research’s HADI™ index at 582.8 — means the legal, ethical, and patient safety frameworks governing clinical AI use have not kept pace with frontline deployment. Separately, only 15.5% of FDA-authorized AI medical devices from 2024 provided demographic data on their validation cohorts (Keller et al., PMC 2025), creating representational gaps that governance frameworks haven’t yet systematically addressed.
See also Digital Health Statistics · Telehealth Statistics · AI Agents in Healthcare Statistics · AI Drug Discovery Statistics ·